Form 4 Filing for Uri Yablonka - EVP & Chief Business Officer of BRAINSTORM CELL THERAPEUTICS INC.

This filing details a Form 4 submission by Uri Yablonka, EVP & Chief Business Officer of BRAINSTORM CELL THERAPEUTICS INC. On February 26, 2026, Yablonka acquired 150,000 shares of common stock through the vesting of restricted stock units (RSUs) awarded under a company plan. These RSUs vest in two tranches: 50% upon grant and the remaining 50% six months later, contingent upon continued employment. The acquisition was reported with a transaction price of $0.00 per share, indicating it was part of a compensation award. Following this transaction, Yablonka holds a total of 218,464 shares. The shares acquired are directly owned.